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SUPPLEMENT 
I. Supplemental Methods 
Supplemental methods 1: Need for Cognition Scale 
The self-report Need for Cognition Scale (Cacioppo & Petty, 1982; Cacioppo, Petty, & Kao, 
1984) was administered to investigate participants’ tendency (trait)  to engage in effortful 
tasks. The scale consists of 18 statements, which participants rate on a 5-point Likert scale 
(“extremely uncharacteristic of me” to “extremely characteristic of me”). Example 
statements include “I prefer complex to simple problems” or “I only think as hard as I have 
to”.  Scores range from 18 to 90. Results of the relation between participants’ need for 
cognition scores and their degree of demand avoidance are presented in the supplemental 
results (see Supplemental Results 4). In this study, we did not have specific hypotheses for 
this scale, but aimed to relate to existing work by reporting whether demand avoidance as 
quantified with the demand selection task relates to this measure. Thus, we correlated the 
proportion of low-demand choices (i.e. demand avoidance) to participants’ scores on the 
Need for Cognition scale using IBM SPSS for Windows, version 21 (IBM Corp., Armonk, N.Y., 
USA). 
 
Supplemental methods 2: Statistical analyses – additional control analyses  
We performed a number of control analyses using a model comparison approach, where we 
assessed whether the residual sum of squares was reduced when adding any of the following 
factors: order effects of drug and testing day, gender, and NLV scores (as a measure of verbal 
intelligence). Results of these control analyses are presented in Supplemental Results 5 and 
Supplemental Table 6.  
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To assess whether our key MPH effects of interest can be accounted for by nonspecific 
effects of MPH on mood and medical symptoms, we extracted subjective ratings of the PANAS 
scale (Watson, Clark, & Tellegen, 1988), Bond and Lader Visual Analogue Scale (Bond & 
Lader, 1974) and the medical analogue scale (Supplemental Material 2) and performed a 
repeated measures MANOVA with the within-subject factors Time (3: start of testing day, 
before task battery, after task battery) and Drug (2: MPH, placebo) and the six measures as 
dependent variables (positive affect, negative affect, calmness, alertness, contentedness, 
medical symptoms) using IBM SPSS for Windows, version 21 (IBM Corp., Armonk, N.Y., USA). 
Significant effects were followed up with repeated measure ANOVA. Results are presented 
in Supplemental Results 5. 
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Supplemental Material 1: Overview of exclusion criteria 
 (History of) psychiatric treatment 
 (History of) neurological treatment 
 (History of) endocrine treatment 
 (History of) autonomic failure (e.g., vasovagal reflex syncope). 
 (History of) clinically significant hepatic, cardiac, obstructive respiratory, renal, 
cerebrovascular, metabolic or pulmonary disease 
 Family history of sudden death or ventricular arrhythmia 
 (History of) epilepsy 
 (History of) drug dependence (opiate, LSD, (meth)amphetamine, cocaine, solvents, 
or barbiturate) or alcohol dependence 
 Suicidality 
 Abnormal hearing or (uncorrected) vision. 
 Use of MAO inhibitor, anaesthetic, anti-depressant or antipsychotic drugs within the 
week prior to the start of the study. 
 Use of psychotropic medication, or of recreational drugs over a period of 24 hours 
prior to each test session, and use of alcohol within the last 24 hours before each 
measurement. 
 Regular use of corticosteroids. 
 Uncontrolled hypertension, defined as diastolic blood pressure at rest > 95 mmHg 
or systolic blood pressure at rest > 180 mmHg 
 Hypotension, defined as diastolic blood pressure < 50 mm Hg or systolic < 95 mm 
Hg or resting pulse rate < 45 beats/min 
 Diabetes  
 Family history of schizophrenia, bipolar disorder or major depressive disorder 
 Irregular sleep/wake rhythm (e.g., regular nightshifts or cross timeline travel).  
 Possible pregnancy or breastfeeding 
 Lactose intolerance (placebo pill is a lactose product) 
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Supplemental Material 2: Medical symptoms rating scale 
1. No headache    Strong headache 
2. No muscle pain   Strong muscle pain 
3. No dry mouth   Very dry mouth 
4. Not dizzy    Very dizzy 
5. No abdominal pain   Strong abdominal pain 
6. No joint pain    Strong joint pain 
7. No trouble breathing  Trouble breathing 
8. No throat pain   Strong throat pain 
9. No chest pain    Strong chest pain 
10. No eye problems   Strong eye problems 
 
 
II. Supplemental Results 
 
Supplemental Results 1: Effects of MPH as a function of working memory capacity 
Listening span scores varied from 2.5 to 7 with a median of 4.5. This median and range is 
comparable with values observed in previous studies including young populations 
(Salthouse & Babcock, 1991). The listening span-dependent effects of MPH, described in the 
main text, are shown in Supplemental Figures 4A and 4B. 
Supplementary analysis after exclusion of participants who failed to explore at all, 
who switched cues on every trial, for whom the capsule dissolved early as well as an outlier 
on trait impulsivity scores also did not reveal any significant MPH-effects as a function of 
working-memory capacity (n = 74: Drug x Listening span: X2(1) = 0.68, p = 0.408).   
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MPH did alter the reaction time demand cost as a function of listening span (Drug x 
Listening span x Demand: X2(1) = 4.11, p = 0.043; Supplemental Figure 5A). High-span 
participants exhibited MPH-induced decreases in the RT demand cost, whereas low-span 
participants exhibited MPH-induced increases in the RT demand cost. However, note that in 
a model that takes into account response stickiness (see Supplemental Results 2 and 
Supplemental Table 5), this interaction did not reach significance (Drug x Listening span x 
Demand: X2(1) = 3.63, p = 0.057). There was no span-dependent effect on the error demand 
cost: Drug x Listening span x Demand: X2(1) = 0.20, p = 0.657, Supplemental Figure 5B). 
In sum, relative to low working memory-span participants, high-span participants 
(tend to) exhibit MPH-induced improvement in task switching (in terms of RT demand 
costs), but MPH did not affect demand avoidance robustly as a function of working memory. 
We are puzzled by the lack of an effect of WM capacity, particularly given the effect of trait 
impulsivity, which has also been associated with dopamine transmission. We raise two 
alternative accounts of this pattern, although we also note that we do not provide evidence 
for a significantly greater impact of impulsivity than of WM capacity. First, trait impulsivity 
might be a more reliable proxy of baseline dopamine levels than WM capacity. We would 
argue this is unlikely, particularly given the subjective, self-report nature of the former and 
not the latter proxy variable. Second, trait impulsivity might index a distinct aspect of 
dopamine transmission (striatal dopamine release; Buckholtz et al., 2010; Dalley et al., 2007) 
that might be more determinant of the effect of MPH on demand avoidance than the 
dimension captured by WM capacity (striatal and probably prefrontal dopamine synthesis 
capacity).  
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Our hypothesis regarding WM span was bi-directional. The finding of beneficial MPH-
effects in high-span participants contrasts with prior evidence, showing greater potentiation 
by MPH of performance on working memory and sustained attention tasks in low- than high-
span participants (Del Campo et al., 2013; Mehta et al., 2000). However, on hindsight, the 
positive correlation between WM span and MPH effects is not surprising, given that, as is the 
case for impulsivity (Buckholtz et al., 2010), WM span is also associated with higher striatal 
dopamine function. Moreover, our effect generally concurs with other evidence, indicating, 
conversely, greater potentiation by MPH of learning in high- than low-capacity subjects (van 
der Schaaf, Fallon, Ter Huurne, Buitelaar, & Cools, 2013) as well as greater MPH-induced 
increases in dopamine release in higher-performing participants (Del Campo et al., 2013). 
Finally, it fits with the dopamine cell-activity hypothesis (Volkow et al., 2002) suggesting that 
DAT blockade (with MPH) induces larger dopamine increases in subjects with high relative 
to low dopamine cell activity. We remain puzzled by these discrepant effects of working 
memory span across studies, but speculate that they reflect catecholaminergic modulation 
of different neural regions with distinct optimal levels of dopamine (e.g. Fallon and Cools, 
2015). For example, the enhancing effects of MPH on learning and task switching might 
reflect catecholaminergic modulation of the striatum, whereas the impairing effects of MPH 
on working memory and sustained attention, reported previously, might reflect modulation 
of the prefrontal cortex, consistent with the disproportionate vulnerability of the prefrontal 
cortex to supra-optimal dopamine (D1) receptor stimulation (Berridge & Arnsten, 2015; 
Seamans & Yang, 2004; Vijayraghavan, Wang, Birnbaum, Williams, & Arnsten, 2007; 
Williams & Goldman-Rakic, 1995). Clearly this speculative hypothesis should be tested using 
pharmacological fMRI.  
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Supplemental Results 2: Performance models including stay regressor 
For the purpose of consistency with our approach for the choice analyses, we re-ran the 
performance models (accuracy and response times), when including the response stickiness 
regressor as main effect and interacting effect with MPH (and demand). We then did model 
comparisons using the anova function in R to assess whether the reduction in the residual 
sum of squares is statistically significant compared with the simpler models. For accuracy, a 
model without any stickiness regressor shows the smallest BIC (31220). Adding a stickiness 
regressor did not reduce residual sum of squares significantly (versus main effect of 
stickiness: X2 (6) = 3.6, p = 0.733; versus interactive effect of stickiness: X2 (30) = 21.5, p = 
0.872). For response times, however, the model with the lowest BIC that shows a significant 
reduction of residual sum of squares compared with the other two models, is a model that 
includes stickiness as interactive term (BIC = 137710, versus basic model: X2 (30) = 2575.3, 
p < 0.001); versus stickiness main effect: X2 (24) = 2113.5, p < 0.001). Results of this winning 
model are presented in Supplemental Table 5. 
 
Supplemental Results 3: Performance models including task-switching 
Participants’ choices of low versus high demand options determine the degree of task-
switching that they encounter and therefore also the ‘practice’ of one or the other trial type. 
To quantify this effect, we re-ran performance models (Supplemental Table 1, bottom), but 
now including the factor task-switching as predictor in addition to demand. The model 
confirms that switch-costs are larger on low demand trials relative to high demand trials. 
This only holds for response times (task-switch x demand interaction: X2(1) = 372.7, p < 
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0.001), and not for accuracy (task-switch x demand interaction: X2(1) = 0.4, p = 0.547. 
Critically, this interaction in response times was not modulated by MPH (Drug x task-switch 
x demand: X2(1) = 1.8, p = 0.179), also not as a function of impulsivity scores (Drug x task-
switch x demand x Impulsivity: X2(1) = 1.2, p = 0.266). 
 
Supplemental Results 4: Need for Cognition Scale and demand avoidance 
Participants’ average score on the Need for Cognition (NFC) scale was 63.3 (SD = 10.5) 
ranging from 38 to 82. These values are comparable with those reported previously (e.g. 
Westbrook et al., 2013). The Need for Cognition score did not correlate with the degree of 
demand avoidance in the placebo (NFC & low demand choices: r = 0.13, p = 0.212), in the 
MPH session (NFC & low demand choices: r = -0.07, p = 0.498) or with the effect of MPH 
relative to placebo on demand avoidance (NFC & low demand choices MPH – PLA: r = -0.15, p = 
0.133).  
Supplemental Results 5: Additional control analyses 
We performed model comparisons with models including potentially confounding variables 
of no interest. We included the factors order of intervention, testing day, gender, and verbal 
intelligence (NLV) separately as fixed between-subject factors in the basic models, resulting 
in 12 comparisons presented in Supplemental Table 6. Models including order, day, gender 
or NLV did not explain more variance than the basic models, except for adding the factor day 
to the response time model. Including day (BIC = 139860) explained significantly more 
variance than the basic model (BIC = 139935; X2(1) = 86.60, p < 0.001). However, significance 
and interpretation of reported effects were not altered in a model including day. 
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The administration of MPH altered participants’ mood ratings (positive affect, 
negative affect, alertness, contentedness, calmness) and medical symptoms (Supplemental 
Material 2) significantly (MANOVA: Drug x Time [3]: V = 0.28, F(6,12) = 5.30, p < 0.001) in 
the absence of differences at time zero before drug administration (Drug: V = 0.06, F(6, 93) 
= 0.91, p = 0.492). MPH increased subjective report of positive affect (F(1,98) = 18.26, p < 
0.001), alertness (F(1,98) = 16.88, p < 0.001), medical symptoms (F(1,98) = 9.60, p = 0.003) 
and decreased calmness (F(1,98) = 8.65, p = 0.004), all with respect to baseline (Drug x Time, 
measurement 1 versus later). To explore whether these mood and medical measures 
differed between dug sessions at the time point most proximal to the demand selection task, 
we conducted the same analysis again for the second time point and assessed whether this 
interacts with impulsivity scores. Results of this repeated measures MANOVA reveal no 
significant modulation across all measures in multivariate (Drug x Impulsivity: F(6,93) = 
1.31, p = 0.260) nor for each measure in univariate tests. In addition, when correlating drug-
induced changes on all six mood and medical measures at this same time point with drug-
induced changes in demand avoidance, none of these correlations reached significance (all 
p-values > 0.2). In sum, it is unlikely that MPH-induced mood or medical changes underlie 
our effect of interest: an impulsivity-dependent modulation of demand avoidance. 
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Supplemental Figure 1 - Histogram of the proportion of participant’s response switches 
between the two choice options as a function of drug. A high frequency of participants 
showed low exploration of the two choice options. Choices of 3 participants deviated more 
than 3 standard deviations from the group’s mean regarding their extreme exploration 
behavior on placebo and methylphenidate sessions (proportion switching above 0.99).  
 
 
Note that this low rate of exploration would have resulted in extremely skewed distribution of our 
dependent variable of interest, i.e. demand avoidance. However, by making use of 8 different task 
blocks where low and high demand options appear at different locations and have different visual 
identities, the key variable of demand avoidance is not significantly skewed. The distribution of the 
variable of interest, the proportion of low demand choices, is depicted in Figure 2B.  
 
Supplemental Figure 2 –Methylphenidate-effect on demand avoidance as a function of 
participants’ trait impulsivity (BIS-11) scores for the reduced sample (n = 74). Line 
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represents model-based estimated coefficients of MPH-effect on demand avoidance as a 
function of (z-scored) trait impulsivity scores. Shaded area represents simulated 95% 
confidential intervals of the coefficients. The inset shows the raw data: drug effect for every 
participant (n = 74) across trials as the difference in the proportion of low demand choices 
(MPH - placebo) as a function of trait impulsivity.  
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Supplemental Figure 3- Methylphenidate-effect on demand avoidance varied as a function 
of participants’ trait impulsivity. Data points represent proportion of low demand choices 
averaged across participants (n = 100) across 8 blocks for A low and B high impulsive 
participants as a function of trial. Three participants with median scores are not included in 
this plot.  
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Supplemental Figure 4 – Methylphenidate (MPH)-effect on demand avoidance as a function 
of participants’ working memory capacity does not reach statistical significance. Data points 
represent effects of MPH, relative to placebo, on the proportion of low demand choices (MPH 
minus placebo). A Line represents model-based estimated coefficients of MPH-effect on 
demand avoidance as a function of (z-scored) listening span total scores. Shaded area 
represents simulated 95% confidential intervals of the coefficients. The inset shows the raw 
data: drug effect for every participant (n = 100) across trials as the difference in the 
proportion of low demand choices (MPH - placebo) as a function of listening span scores. B 
Trial-by-trial drug effect averaged across 8 blocks, and across participants (n = 100) of low 
(n = 23), medium (n = 31) and high (n = 46) listening span groups as a function of trial. 
Shaded areas represent standard error of the difference.  
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Supplemental Figure 5 - Drug effects on demand cost in response times (RTs) and accuracy. 
Data points represent methylphenidate (MPH)-effects on average demand cost (MPH minus 
placebo) for each participant for A response times as a function of working memory capacity 
(listening span total, significant, p = 0.043) and B accuracy as a function of working memory 
capacity (listening span total, not significant, p = 0.657). Shaded areas represent standard 
errors of the difference. 
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Supplemental Table 1: Overview of regression models 
Dependent variable Regression models 
Choice 
category: binary 
 
Choice ~ 
Drug x Impulsivity + Drug x Listening span 
+ (1 + Drug | Participant) 
Choice with  
stay regressor 
 
Choice ~ 
Drug x Impulsivity + Drug x Listening span  
+ Stay 
+ (1 + Drug + Stay | Participant) 
Choice with  
MPH-effect on 
stay regressor 
 
 
Choice ~ 
Drug x Impulsivity + Drug x Listening span  
+ Drug x Stay 
+ (1 + Drug x Stay | Participant) 
Accuracy 
category: binary 
 
Accuracy ~ 
Drug x Impulsivity x Demand  
+ Drug x Listening span x Demand 
+ (1 + Drug x Demand | Participant) 
Response times 
category: 
continuous  
 
RT ~ 
Drug x Impulsivity x Demand  
+ Drug x Listening span x Demand 
+ (1 + Drug x Demand | Participant) 
 
Supplemental Table 2: Logistic regression coefficients indicating the influence of drug, 
impulsivity, listening span, choice on previous trial (staying) and their interactions with drug 
on participants’ choices (n = 100). Bold p-values denote significance. For this model, the 
marginal R2GLMM is 0.639.    
Coefficient Estimate (SE) X2(1) p 
Intercept -0.184 (0.04) 20.70 < 0.001 
Drug  -0.001 (0.03) < 0.01 0.964 
Drug x Impulsivity 0.009 (<0.01) 5.33 0.021 
Drug x Listening span 0.052 (0.03) 2.91 0.088 
Impulsivity -0.001 (0.01) 0.07 0.793 
Listening span -0.029 (0.04) 0.57 0.451 
Staying -4.239 (0.25) 291.16 < 0.001 
Drug x Staying 0.238 (0.09) 7.65 0.006 
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Supplemental Table 3: Performance and choice statistics of effects of interest after the 
exclusion of participants who failed to explore the choice options at all, either in one (n = 17) 
or both session (n = 5), those who switched choice options on every cue in one (n =1) or both 
(n = 1) sessions , those for whom the capsule dissolved (orally or in water) before swallowing 
(n = 2, one of those was also a sticky participant) as well as one participant whose score on 
the BIS-11 impulsiveness questionnaire deviated more than 3 standard deviations from the 
mean. Analysis of this smaller dataset (n = 74) confirmed the effects obtained from the 
analysis of the larger sample. Marginal R2GLMM of the choice, accuracy and response times 
models are 0.698, 0.013 and 0.090, respectively.  
 Choice Accuracy Response times 
Coefficient X2(1) p X2(1) p X2(1) p 
Drug  0.03 0.867 5.91 0.015 1.85 0.173 
Drug x Imp 5.80 0.016 0.02 0.876 8.87 0.003 
Drug x LSpan 0.68 0.408 0.69 0.408 1.92 0.165 
Drug x Demand N/A N/A 1.46 0.228 0.31 0.580 
Drug x Imp x Demand N/A N/A 1.01 0.315 0.10 0.754 
Drug x LSpan x Demand N/A N/A 0.17 0.679 0.64 0.425 
Stay 465.64 < 0.001 N/A N/A N/A N/A 
Drug x Stay 4.80 0.029 N/A N/A N/A N/A 
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Supplemental Table 4: (Logistic) regression coefficients indicating the influence of drug, 
impulsivity (Imp), listening span (LSpan), task demand and their interactions on 
participants’ performance (n = 100). Bold p-values denote significance. Marginal R2GLMM of 
the accuracy and response times models are 0.011 and 0.086, respectively. 
 Accuracy Response times 
Coefficient Estimate (SE) X2(1) p Estimate (SE) X2(1) p 
Intercept 3.868 (0.10) 1469.47 < 0.001 -0.123 (0.02) 45.22 < 0.001 
Drug  -0.112 (0.04) 7.29 0.007 0.016 (0.01) 2.98 0.084 
Drug x Imp 0.001 (0.01) 0.10 0.747 0.003 (<0.01) 7.28 0.007 
Drug x LSpan 0.012 (0.04) 0.10 0.748 0.012 (0.01) 1.92 0.166 
Imp 0.015 (0.01) 1.57 0.211 0.002 (<0.01) 1.12 0.289 
LSpan -0.045 (0.09) 0.23 0.635 -0.024 (0.02) 1.95 0.163 
Demand 0.106 (0.03) 15.50 < 0.001 -0.139 (0.01) 535.73 < 0.001 
Drug x Demand -0.027 (0.02) 1.20 0.274 -0.003 (<0.01) 0.75 0.387 
Drug x Imp x Demand <0.001 (<0.01) <0.01 0.968 -0.000 (<0.01) 0.29 0.590 
Drug x LSpan x Demand -0.008 (0.02) 0.20 0.657 -0.007 (<0.01) 4.11 0.043 
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Supplemental Table 5: Regression coefficients indicating the influence of drug, impulsivity 
(Imp), listening span (LSpan), task demand, choice on previous trial (Stay) and their 
interactions on participants’ response times (n = 100). Bold p-values denote deviations in 
significance relative to the basic RT model that did not account for response stickiness. Note 
that conclusions presented in the main text are unaltered. 
 Response times 
Coefficient Estimate (SE) X2(1) p 
Intercept 0.08 (0.02) 10.60 <0.001 
Drug  0.004 (0.01) 0.15 0.700 
Drug x Imp 0.003 (<0.01) 7.96 0.005 
Drug x LSpan 0.012 (0.01) 2.05 0.152 
Imp 0.002 (<0.01) 1.16 0.281 
LSpan -0.018 (0.02) 1.11 0.293 
Demand -0.076 (<0.01) 152.39 < 0.001 
Drug x Demand -0.002 (0.01) 0.17 0.681 
Drug x Imp x Demand -0.000 (<0.01) 0.36 0.548 
Drug x LSpan x Demand -0.006 (<0.01) 3.63 0.057 
Stay -0.070 (0.01) 173.84 <0.001 
Drug x Stay -0.002 (0.01) 0.16 0.687 
Drug x Demand x Stay 0.011 (0.01) 2.38 0.123 
 
Supplemental Table 6: Model comparison of basic models with control models. Bold p-
values denote significance. 
  Basic + NLV + Day + Order + Gender 
Choice  
 
BIC 
sign. 
150826 150838 
p = 0.501 
150835 
p = 0.079 
150837 
p = 0.464 
150835 
p = 0.105 
Accuracy  BIC 
sign. 
31220 31232 
p = 0.695 
31231 
p = 0.509 
31232 
p = 0.931 
31232 
p = 0.924 
Response times  BIC 
sign. 
139935 139946 
p < 0.364 
139860 
p < 0.001 
139946 
p = 0.436 
139947 
p = 0.806 
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